News for Ensysce Biosciences, Inc. (ENSC)

Ensysce Biosciences, known by its ticker ENSC, has commenced a critical Phase 3 clinical trial for its leading product candidate, PF614. This study, titled PF61

~ PF614-MPAR Moving to Next Stage of Development, Finalizing Drug Formulation ~~ Funds Accelerate Path Towards Commercialization ~ SAN DIEGO, CA / ACCESS Newswi

Ensysce Biosciences (ENSC) has received the second installment of $5.3 million from a $15 million grant provided by the National Institute on Drug Abuse. This f

Ensysce Biosciences (ENSC) secured a $5.3 million grant from NIDA, part of a $15 million commitment. PF614-MPAR, the innovative opioid therapy, has

Receives U.S. Patent for Groundbreaking Treatment for Opioid Use DisorderClinical Trial on Novel Analgesic, PF614-MPAR, Demonstrates Overdose Protection SAN DIE

Ensysce Biosciences (ENSC) reported a Q1 2025 net loss of $1.9M, an improvement from a $3.1M loss in Q1 2024. The company received a U.S. patent for PF9

~ Advanced Preparation for New Drug Application ~ SAN DIEGO, CA / ACCESS Newswire / May 12, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Co

SAN DIEGO, CA / ACCESS Newswire / April 24, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage pharmaceutical company developing i

Ensysce Biosciences (ENSC) secures $2.2 million in gross proceeds through warrant exercise. New warrants issued allow purchase of 1,260,752 shares at an

Japan-based Linkage Global Inc (LGCB) is up over 24 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Shares of ServiceNow, Inc. NOW rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results. Serv...

Ensysce Biosciences, Inc. (ENSC) raises $2.2 million through warrant exercises, bolstering its pain management development initiatives. Analysts predict

Ensysce Biosciences shares skyrocket nearly 100% after securing a key patent for its innovative methadone prodrug. Analysts project significant upside p

SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 23, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage pharmaceutical company deve

Key Highlights: Ensysce Biosciences has raised approximately $2.2 million through strategic warrant agreements. New warrants are set to be issued, potent

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 500 points on Wednesday. The Dow traded up 1.29% to 39,693.36 whil...

Ensysce Biosciences Inc (ENSC) has concluded the first part of its key clinical trial for PF614-MPAR, showcasing enhanced safety in opioid use. Wall Str

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 1,000 points on Wednesday. Following the market opening Wednesday, the Dow t...

California-based Ensysce Biosciences, Inc. (ENSC) is up over 133 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.